青蒿琥酯-苯芴醇在幼儿和孕妇中的药代动力学-药效学荟萃分析
该研究通过荟萃分析31项临床研究、4122例患者数据,构建苯芴醇群体药代动力学模型。发现体重<15kg儿童、15-25kg儿童及孕妇第7天苯芴醇浓度分别比非孕成人低24.2%、13.4%和20.2%。模拟提示延长给药方案(每日两次共5天)或增加给药频率(每日三次共3天)比提高单次剂量更有效。
要点
- 幼儿和孕妇苯芴醇暴露量显著低于非孕成人。
- 延长疗程或增加给药频率可能优于提高单次剂量。
- 优化方案需前瞻性临床研究验证疗效与安全性。
核心结论
- 幼儿和孕妇需调整青蒿琥酯-苯芴醇方案以改善药物暴露。
- 延长或复杂化给药方案可能提高疗效但需临床验证。
研究设计与样本
- 荟萃分析纳入31项临床研究,共4546例测定苯芴醇浓度。
- 汇总4122例患者个体浓度-时间、协变量和结局数据。
- 构建群体药代动力学模型并进行计算机模拟剂量优化。
主要发现
- 体重<15kg儿童第7天苯芴醇浓度比非孕成人低24.2%。
- 体重15-25kg儿童第7天浓度低13.4%。
- 孕妇第7天浓度低20.2%。
- 苯芴醇暴露随治疗前寄生虫血症升高而降低。
- 苯芴醇吸收存在显著剂量限制。
关键数值与推荐
- 模拟提示每日两次共5天或每日三次共3天优于提高单次剂量。
- 优化方案基于第7天静脉血浆苯芴醇暴露药代动力学终点。
临床怎么用
- 当前标准方案(每日两次共3天)在幼儿和孕妇中暴露不足。
- 可考虑延长疗程至5天或增加给药频率至每日三次共3天。
- 优化方案需在前瞻性临床研究中验证治愈率和安全性。
局限性
- 模型基于完整药片随脂质服用的静脉血浆数据。
- 缺乏青蒿琥酯-双氢青蒿素数据限制预测寄生虫杀灭率。
- 替代方案仅代表完整药片随脂质服用后的静脉血浆暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The fixed dose combination of artemether-lumefantrine (AL) is the most widely used treatment for uncomplicated Plasmodium falciparum malaria. Relatively lower cure rates and lumefantrine levels have been reported in young children and in pregnant women during their second and third trimester. The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of lumefantrine and the pharmacokinetic properties of its metabolite, desbutyl-lumefantrine, in order to inform optimal dosing regimens in all patient populations. METHODS AND FINDINGS: A search in PubMed, Embase, ClinicalTrials.gov, Google Scholar, conference proceedings, and the WorldWide Antimalarial Resistance Network (WWARN) pharmacology database identified 31 relevant clinical studies published between 1 January 1990 and 31 December 2012, with 4,546 patients in whom lumefantrine concentrations were measured. Under the auspices of WWARN, relevant individual concentration-time data, clinical covariates, and outcome data from 4,122 patients were made available and pooled for the meta-analysis. The developed lumefantrine population pharmacokinetic model was used for dose optimisation through in silico simulations. Venous plasma lumefantrine concentrations 7 days after starting standard AL treatment were 24.2% and 13.4% lower in children weighing <15 kg and 15-25 kg, respectively, and 20.2% lower in pregnant women compared with non-pregnant adults. Lumefantrine exposure decreased with increasing pre-treatment parasitaemia, and the dose limitation on absorption of lumefantrine was substantial. Simulations using the lumefantrine pharmacokinetic model suggest that, in young children and pregnant women beyond the first trimester, lengthening the dose regimen (twice daily for 5 days) and, to a lesser extent, intensifying the frequency of dosing (3 times daily for 3 days) would be more efficacious than using higher individual doses in the current standard treatment regimen (twice daily for 3 days). The model was developed using venous plasma data from patients receiving intact tablets with fat, and evaluations of alternative dosing regimens were consequently only representative for venous plasma after administration of intact tablets with fat. The absence of artemether-dihydroartemisinin data limited the prediction of parasite killing rates and recrudescent infections. Thus, the suggested optimised dosing schedule was based on the pharmacokinetic endpoint of lumefantrine plasma exposure at day 7. CONCLUSIONS: Our findings suggest that revised AL dosing regimens for young children and pregnant women would improve drug exposure but would require longer or more complex schedules. These dosing regimens should be evaluated in prospective clinical studies to determine whether they would improve cure rates, demonstrate adequate safety, and thereby prolong the useful therapeutic life of this valuable antimalarial treatment.
引用
- Kloprogge F, Workman L, Borrmann S, et al. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med. 2018. PMID: 29894518. doi:10.1371/journal.pmed.1002579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。